Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial is a research paper published in Journal of Clinical Oncology (2022). On theSindex it has a DataRank of 2.6. It has been cited 88 times, with 84 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.673
From this paper's citation signal
Citation Network Contribution
1.9
From 72 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 84 citers.
NCI NIH HHS
Grant: U10 CA180863
NCI NIH HHS
Grant: U24 CA180803
NCI NIH HHS
Grant: U10 CA180868
NCI NIH HHS
Grant: U10 CA180822
NCI NIH HHS
Grant: UG1 CA233290
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: UG1 CA233191
National Institutes of Health
Grant: 3U24CA180803-06S1
Imaging and Radiation Oncology Core (IROC) Group
National Institutes of Health
Grant: 5U10CA180863-08
Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network
National Institutes of Health
Grant: 5U10CA180868-09
NRG Oncology Network Group Operations Center
National Institutes of Health
Grant: 2U10CA180822-06
NRG Oncology - Statistical and Data Management Center
FWCI
7.53
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals